MCID: SCK005
MIFTS: 54

Sickle Cell Disease

Categories: Immune diseases, Blood diseases

Aliases & Classifications for Sickle Cell Disease

MalaCards integrated aliases for Sickle Cell Disease:

Name: Sickle Cell Disease 23 24 51 3
Sickling Disorder Due to Hemoglobin S 24
Sickle Cell Disorders 24
Hemoglobin S Disease 24
Anemia, Sickle Cell 69
Hbs Disease 24
Scd 24

Classifications:



External Ids:

ICD10 32 D57

Summaries for Sickle Cell Disease

Genetics Home Reference : 24 Sickle cell disease is a group of disorders that affects hemoglobin, the molecule in red blood cells that delivers oxygen to cells throughout the body. People with this disorder have atypical hemoglobin molecules called hemoglobin S, which can distort red blood cells into a sickle, or crescent, shape.

MalaCards based summary : Sickle Cell Disease, also known as sickling disorder due to hemoglobin s, is related to hereditary persistence of fetal hemoglobin-sickle cell disease syndrome and acute chest syndrome, and has symptoms including edema, chest pain and angina pectoris. An important gene associated with Sickle Cell Disease is HBB (Hemoglobin Subunit Beta), and among its related pathways/superpathways are Glucose / Energy Metabolism and Factors involved in megakaryocyte development and platelet production. The drugs Iron and Hydroxyurea have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and kidney, and related phenotypes are Increased shRNA abundance and cardiovascular system

Wikipedia : 72 Sickle-cell disease (SCD) is a group of blood disorders typically inherited from a person\'s parents.... more...

GeneReviews: NBK1377

Related Diseases for Sickle Cell Disease

Diseases related to Sickle Cell Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 242)
# Related Disease Score Top Affiliating Genes
1 hereditary persistence of fetal hemoglobin-sickle cell disease syndrome 32.9 BCL11A HBB HBG1 HBG2
2 acute chest syndrome 32.3 HBB VCAM1
3 splenic sequestration 31.2 BCAM HBB
4 malaria 30.8 EPO G6PD HBA2 HBB SELP VCAM1
5 hemoglobinopathy 30.7 EPO HBA2 HBB HBD HBG1 UGT1A1
6 sickle cell anemia 30.3 BCL11A EPO G6PD HBA2 HBB HBG1
7 hemoglobin c disease 29.8 HBB HBD
8 hereditary spherocytosis 29.5 G6PD HBB HBG1 UGT1A1
9 hemolytic anemia 29.4 G6PD HBA2 HBB
10 glucosephosphate dehydrogenase deficiency 29.3 G6PD HBB HBG2 UGT1A1
11 deficiency anemia 28.8 EPO G6PD HBA2 HBB HBG2
12 thalassemia 28.7 BCL11A EPO HBA2 HBB HBD HBG1
13 alpha-thalassemia 27.9 EPO G6PD HBA2 HBB HBG1 HBG2
14 beta-thalassemia 27.1 BCL11A EPO G6PD HBA2 HBB HBD
15 sickle cell disease associated with an other hemoglobin anomaly 12.0
16 schnyder corneal dystrophy 11.6
17 superior semicircular canal dehiscence 11.5
18 cardiac conduction defect 11.3
19 sickle beta thalassemia 11.2
20 fatty liver disease 11.1
21 qt interval, variation in 11.1
22 ehlers-danlos syndrome, spondylodysplastic type, 3 11.1
23 diabetes mellitus, noninsulin-dependent 11.1
24 body mass index quantitative trait locus 11 11.1
25 reye syndrome 11.1
26 clear cell renal cell carcinoma 11.1
27 fetal hemoglobin quantitative trait locus 5 10.9
28 endosteal hyperostosis, autosomal dominant 10.9
29 osteomesopyknosis 10.9
30 moyamoya disease 1 10.9
31 episodic pain syndrome, familial, 1 10.5
32 priapism 10.4
33 methemoglobinemia, beta-globin type 10.4 HBA2 HBB
34 splenic disease 10.3 EPO HBB
35 heinz body anemias 10.3 HBA2 HBB
36 hypochromic microcytic anemia 10.3 HBA2 HBB
37 acute erythroid leukemia 10.3 EPO HBB HBG1
38 pulmonary hypertension 10.2
39 endotheliitis 10.2
40 neonatal anemia 10.2 EPO HBA2 HBG1
41 aging 10.2
42 avascular necrosis of femoral head, primary, 1 10.2
43 cholelithiasis 10.2
44 cerebritis 10.2
45 glutathione peroxidase deficiency 10.2 HBA2 HBB SELP
46 multiple symmetrical lipomatosis 10.2 SELP VCAM1
47 retinitis 10.1
48 acquired methemoglobinemia 10.1 G6PD HBG2
49 asthma 10.1
50 hemosiderosis 10.1

Graphical network of the top 20 diseases related to Sickle Cell Disease:



Diseases related to Sickle Cell Disease

Symptoms & Phenotypes for Sickle Cell Disease

UMLS symptoms related to Sickle Cell Disease:


edema, chest pain, angina pectoris, abdominal pain

GenomeRNAi Phenotypes related to Sickle Cell Disease according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance GR00327-A 8.92 EPO G6PD HBD HBG2

MGI Mouse Phenotypes related to Sickle Cell Disease:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.23 BCAM EPO G6PD KCNN4 PGF SELP

Drugs & Therapeutics for Sickle Cell Disease

Drugs for Sickle Cell Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 388)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iron Approved Phase 4,Phase 2,Phase 3,Phase 1 7439-89-6 23925
2
Hydroxyurea Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 127-07-1 3657
3
Deferoxamine Approved, Investigational Phase 4,Phase 2,Phase 3 70-51-9 2973
4
Ribavirin Approved Phase 4 36791-04-5 37542
5
Deferiprone Approved Phase 4,Phase 2,Phase 3,Phase 1 30652-11-0 2972
6
Proguanil Approved Phase 4,Phase 1,Phase 2 500-92-5 4923
7
Deferasirox Approved, Investigational Phase 4,Phase 2,Phase 3 201530-41-8 5493381
8
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
9
Peginterferon alfa-2b Approved Phase 4 215647-85-1, 99210-65-8
10
Morphine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 57-27-2 5288826
11
Amodiaquine Approved, Investigational Phase 4,Phase 1,Phase 2 86-42-0 2165
12
Codeine Approved, Illicit Phase 4,Phase 1,Phase 2 76-57-3 5284371
13
Hydromorphone Approved, Illicit Phase 4,Phase 3,Phase 2 466-99-9 5284570
14
Pyrimethamine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 58-14-0 4993
15
Sulfadoxine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 2447-57-6 17134
16
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2 437-38-7 3345
17
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 1,Phase 2 93-14-1 3516
18
Ibuprofen Approved Phase 4,Phase 2 15687-27-1 3672
19
Ketamine Approved, Vet_approved Phase 4,Phase 3,Phase 2 6740-88-1 3821
20
Desogestrel Approved Phase 4 54024-22-5 40973
21
Etonogestrel Approved, Investigational Phase 4 54048-10-1 6917715 40976
22
Heroin Approved, Illicit, Investigational Phase 4 561-27-3 5462328
23
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
24
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 1406-16-2
25
Cholecalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 67-97-0 10883523 5280795 6221
26
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 50-14-6 5280793
27
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1,Early Phase 1 77-92-9 311
28 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
29 interferons Phase 4
30 Respiratory System Agents Phase 4,Phase 3,Phase 2,Phase 1
31 Central Nervous System Depressants Phase 4,Phase 2,Phase 3,Phase 1
32 Micronutrients Phase 4,Phase 2,Phase 3,Phase 1
33 Chelating Agents Phase 4,Phase 2,Phase 3,Phase 1
34 Trace Elements Phase 4,Phase 2,Phase 3,Phase 1
35 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1
36 Vaccines Phase 4,Phase 3,Phase 2,Early Phase 1
37 Anesthetics Phase 4,Phase 2,Phase 3,Phase 1
38 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
39 Anesthetics, General Phase 4,Phase 3,Phase 2,Phase 1
40 Vitamins Phase 4,Phase 2,Phase 3,Phase 1
41 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
42 Ergocalciferols Phase 4,Phase 3,Phase 2,Phase 1
43 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
44 Antimalarials Phase 4,Phase 3,Phase 2,Phase 1
45 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
46 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
47 Interferon-alpha Phase 4
48 Iron Chelating Agents Phase 4,Phase 2,Phase 3,Phase 1
49 Liver Extracts Phase 4,Phase 2,Phase 3,Phase 1
50 Antiprotozoal Agents Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 620)

# Name Status NCT ID Phase Drugs
1 Interferon and Ribavirin Treatment in Patients With Hemoglobinopathies Unknown status NCT00887081 Phase 4 PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin
2 Comparing Acute Pain Management Protocols for Patients With Sickle Cell Disease Completed NCT02222246 Phase 4 Hydromorphone (Standardized, weight-based dosing);Morphine Sulfate (Standardized, weight-based dosing);Hydromorphone (Patient Specific dosing);Morphine Sulfate (Patient Specific dosing)
3 Future of Spermatogenesis in Men With Sickle Cell Disease Medically Treated Completed NCT01609192 Phase 4 Hydrea® (hydroxyurea )
4 Evaluation of the Impact of Renal Function on the Pharmacokinetics of SIKLOS ® (DARH) Completed NCT02522104 Phase 4 Siklos
5 Intranasal Fentanyl for Initial Treatment of a Vaso-occlusive Crisis Completed NCT01482091 Phase 4 Fentanyl Citrate;Normal Saline
6 Pilot Study for Patients With Poor Response to Deferasirox Completed NCT00749515 Phase 4 Deferoxamine;Deferasirox
7 Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other Anemias Recruiting NCT02041299 Phase 4 Deferiprone;Deferoxamine
8 Rejuvesol® Washed RBC in Sickle Cell Patients Requiring Frequent Transfusions Recruiting NCT02731157 Phase 4 Rejuvesol
9 Enhancing Preventive Therapy of Malaria In Children With Sickle Cell Anemia in East Africa (EPiTOMISE) Recruiting NCT03178643 Phase 4 Proguanil Oral Tablet;Sulfadoxine/Pyrimethanine-Amodiaquine (SP-AQ);Dihydroartemisinin-Piperaquine (DP)
10 Contraception in Women With Sickle Cell Disease Active, not recruiting NCT02594462 Phase 4 etonogestrel-releasing implant contraceptive
11 Risk Clinical Stratification of Sickle Cell Disease in Nigeria, Assessment of Efficacy/Safety of Hydroxyurea Treatment Active, not recruiting NCT02149537 Phase 4 hydroxyurea
12 Long-term Safety and Efficacy of Ferriprox® in Iron Overloaded Patients With Sickle Cell Disease or Other Anemias Enrolling by invitation NCT02443545 Phase 4 Deferiprone
13 Mobile-Directly Observed Therapy on Adherence to Hydroxyurea Enrolling by invitation NCT02844673 Phase 4 Hydroxyurea
14 A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT Not yet recruiting NCT03176849 Phase 4
15 Ibuprofen and Opioid (Morphine or Diamorphine) for Acute Pain in Sickle Cell Disease - Sickle With Ibuprofen & Morphine Terminated NCT00880373 Phase 4 Ibuprofen;Placebo;Diamorphine or Morphine
16 Pilot Study on the Effects of Intravenous Ketamine on Acute Pain Crisis in Patients With Sickle Cell Disease Terminated NCT00252122 Phase 4 Ketamine
17 Ketorolac Versus Ibuprofen to Treat Painful Episodes of Sickle Cell Disease Terminated NCT00115336 Phase 4 Intravenous Ketorolac;Ibuprofen
18 Immunogenicity and Safety Study of Pneumococcal 7-Valent Conjugate Vaccine in Sickle Cell Disease Infants. Terminated NCT00368186 Phase 4
19 Assessment of Opioid Analgesia in Sickle Cell Withdrawn NCT00513864 Phase 4 Dextromethorphan;Codeine;Morphine
20 Endothelial Function in Patients With Sickle Cell Anemia Before and After Sildenafil Withdrawn NCT00937144 Phase 4 Viagra (Sildenafil);placebo
21 Transfusion Alternatives Pre-Operatively in Sickle Cell Disease (TAPS) Unknown status NCT00512577 Phase 3
22 Long-Term Effects of Hydroxyurea in Children With Sickle Cell Anemia (The BABY HUG Follow-up Study) Unknown status NCT00890396 Phase 3
23 Study Of Efficacy,Safety of Combined Deferasirox and Deferiprone Versus Combined Deferiprone and Desferal In Conditions of Iron Overload Unknown status NCT01511848 Phase 2, Phase 3 DFP (ferriprox) and deferasirox (ICL 670);DFP, DFO
24 Evaluation of the Lung Capillary Blood Volume in Children With Sickle Cell Disease Completed NCT00560261 Phase 3
25 Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC) Completed NCT01737814 Phase 3 Saline;MST-188
26 L-Arginine and Sickle Cell Disease Completed NCT01142219 Phase 3 L-arginine;Placebo
27 N-Acetylcysteine in Patients With Sickle Cell Disease Completed NCT01849016 Phase 3 N-Acetylcysteine;Placebo
28 Hypnosis to Manage Pain and Symptoms in Patients With Sickle Cell Disease Completed NCT00393250 Phase 3
29 Steroid Treatment for Sickle Cell Pain Crisis Completed NCT00263562 Phase 3 Methylprednisolone plus prednisone taper
30 A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia Completed NCT01179217 Phase 3 L-glutamine;Placebo
31 Evaluation of Repeat Administration of Purified Poloxamer 188 Completed NCT02449616 Phase 3 MST-188
32 Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Children With Sickle Cell Disease Completed NCT00918580 Phase 3
33 Sulfadoxine- Pyrimethamine Versus Weekly Chloroquine for Malaria Prevention in Children With Sickle Cell Anemia Completed NCT00399074 Phase 3 sulfadoxine pyrimethamine
34 Phase III Randomized Study of Poloxamer 188 for Vaso-Occlusive Crisis of Sickle Cell Disease Completed NCT00004408 Phase 3 poloxamer 188
35 Ameliorating Attention Problems in Children With Sickle Cell Disease (SCD) Completed NCT01411280 Phase 3 methylphenidate
36 Multicenter Study of Hydroxyurea in Patients With Sickle Cell Anemia (MSH) Completed NCT00000586 Phase 3 hydroxyurea
37 Intravenous Magnesium for Sickle Cell Vasoocclusive Crisis Completed NCT01197417 Phase 2, Phase 3 Intravenous Magnesium Sulfate;Normal Saline Placebo
38 Hydroxyurea to Prevent Organ Damage in Children With Sickle Cell Anemia Completed NCT00006400 Phase 3 Hydroxyurea;Placebo
39 Penicillin Prophylaxis in Sickle Cell Disease (PROPS) Completed NCT00000585 Phase 3 penicillin
40 Effect of Inhaled Nitric Oxide in Acute Chest Syndrome (INOSTA Study) Completed NCT00748423 Phase 2, Phase 3 Nitric Oxide;Placebo
41 Choosing Opioid Management for Pain and Analyzing Acute Chest Syndrome (ACS) Rates Equally Completed NCT01380197 Phase 3 Morphine;Nubain
42 Silent Cerebral Infarct Transfusion Multi-Center Clinical Trial Completed NCT00072761 Phase 3
43 Novel Use Of Hydroxyurea in an African Region With Malaria Completed NCT01976416 Phase 3 Hydroxyurea;Placebo
44 Stroke Prevention in Sickle Cell Anemia (STOP 1) Completed NCT00000592 Phase 3
45 Stroke Prevention in Sickle Cell Anemia (STOP 2) Completed NCT00006182 Phase 3
46 MAST - Magnesium for Sickle Cell Acute Crisis in Children Completed NCT00313963 Phase 3 Magnesium Sulfate;Normal Saline
47 Mobilization and Handling of Stem Cells for Transplant From Healthy Volunteers With Sickle Cell Trait Completed NCT00005782 Phase 3 Granulocyte colony-stimulating factor
48 Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload Completed NCT00235391 Phase 3 Deferasirox
49 A Trial of Hydroxyurea in Spinal Muscular Atrophy Completed NCT00485511 Phase 2, Phase 3 Hydroxyurea
50 Immunization of Children Between 8 Weeks and 2 Years of Age With GSK Pneumococcal Vaccine GSK1024850A Completed NCT01175083 Phase 3

Search NIH Clinical Center for Sickle Cell Disease

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Genetic Tests for Sickle Cell Disease

Anatomical Context for Sickle Cell Disease

MalaCards organs/tissues related to Sickle Cell Disease:

38
Bone, Bone Marrow, Kidney, Endothelial, Lung, Liver, T Cells

Publications for Sickle Cell Disease

Articles related to Sickle Cell Disease:

(show top 50) (show all 1329)
# Title Authors Year
1
Safety and efficacy of plerixafor dose escalation for the mobilization of CD34+ hematopoietic progenitor cells in patients with sickle cell disease: interim results. ( 29419425 )
2018
2
Improving disease knowledge in 6- to 10-year-olds with sickle cell disease: A quasi-experimental study. ( 29436011 )
2018
3
Children with sickle cell disease migrating to the United States from sub-Saharan Africa. ( 29418070 )
2018
4
Effective screening leads to better outcomes in sickle cell disease. ( 29444869 )
2018
5
Bacteremia and Septic Arthritis due to a Nontoxigenic Strain of<i>Clostridium difficile</i>in a Patient With Sickle Cell Disease. ( 29410974 )
2018
6
Presence of pain on three or more days of the week is associated with worse patient reported outcomes in adults with sickle cell disease. ( 29445298 )
2018
7
Selective Difficulties in Lexical Retrieval and Nonverbal Executive Functioning in Children With HbSS Sickle Cell Disease. ( 29432593 )
2018
8
Phytomedicines (medicines derived from plants) for sickle cell disease. ( 29446825 )
2018
9
Comprehensive management reduces incidence and mortality of acute chest syndrome in patients with sickle cell disease. ( 29205462 )
2018
10
High bone mineral density in sickle cell disease: Prevalence and characteristics. ( 29428552 )
2018
11
Statural Growth and Prevalence of Endocrinopathies in Relation to Liver Iron Content (LIC) in Adult Patients with Beta Thalassemia Major (BTM) and Sickle Cell Disease (SCD). ( 29451227 )
2018
12
Comorbid obstructive sleep apnea and increased risk for sickle cell disease morbidity. ( 29450676 )
2018
13
A phase 1 dose-finding study of intravenous L-citrulline in sickle cell disease: a potential novel therapy for sickle cell pain crisis. ( 29411862 )
2018
14
HO-1<sup>hi</sup>Patrolling Monocytes Protect against Vaso-occlusion in Sickle Cell Disease. ( 29437594 )
2018
15
Malaria, sickle cell disease, HIV and co-trimoxazole prophylaxis: an observational study. ( 29408573 )
2018
16
Early Noninvasive Ventilation and Nonroutine Transfusion for Acute Chest Syndrome in Sickle Cell Disease in Children: A Descriptive Study. ( 29356722 )
2018
17
Lower than expected elevated tricuspid regurgitant jet velocity in adults with sickle cell disease in Nigeria. ( 29438485 )
2018
18
Haploidentical stem cell transplantation cures autoimmune hepatitis and cerebrovascular disease in a patient with sickle cell disease. ( 29335630 )
2018
19
Prevalence and risk factors for venous thromboembolism in children with sickle cell disease: an administrative database study. ( 29431623 )
2018
20
Recurrent Acute Chest Syndrome in Pediatric Sickle Cell Disease: Clinical Features and Risk Factors. ( 29200151 )
2018
21
Imaging for Pulmonary Embolism in Sickle Cell Disease: a 17-Year Experience. ( 29419477 )
2018
22
<i>g(HbF)</i> : a genetic model of fetal hemoglobin in sickle cell disease. ( 29437638 )
2018
23
New NO Donor NCX 1443: Therapeutic Effects on Pulmonary Hypertension in the SAD Mouse Model of Sickle Cell Disease. ( 29438213 )
2018
24
Sickle cell disease; An overview of the disease and its systemic effects. ( 29428339 )
2018
25
Do Alpha Thalassemia, Fetal Hemoglobin, and the UGT1A1 Polymorphism have an Influence on Serum Bilirubin Levels and Cholelithiasis in Patients with Sickle Cell Disease? ( 28567595 )
2017
26
Turf wars: exploring splenomegaly in sickle cell disease in malaria-endemic regions. ( 28493472 )
2017
27
A Fatal Case of Immune Hyperhemolysis with Bone Marrow Necrosis in a Patient with Sickle Cell Disease. ( 28286630 )
2017
28
Red blood cell alloimmunization in patients with sickle cell disease: correlation with HLA and cytokine gene polymorphisms. ( 27873324 )
2017
29
Enhanced Long-Term Brain MRI Evaluation of Children with Sickle Cell Disease Following Hematopoietic Cell Transplantation. ( 28089760 )
2017
30
HLA-Haploidentical Stem Cell Transplant with Pre-Transplant Immunosuppression for Patients with Sickle Cell Disease. ( 28939451 )
2017
31
Bilateral Subperiosteal Hematoma and Orbital Compression Syndrome in Sickle Cell Disease. ( 28938324 )
2017
32
Increased prevalence of renal cysts in patients with sickle cell disease. ( 28934953 )
2017
33
Acute Pain in Adolescents and Young Adults with Sickle Cell Disease: Delayed and Increased Opioid Dosing Following Transition to Adult Care. ( 28066934 )
2017
34
Efficient Generation of I^-Globin-Expressing Erythroid Cells Using Stromal Cell-Derived Induced Pluripotent Stem Cells from Patients with Sickle Cell Disease. ( 27739611 )
2017
35
Extracorporeal Lung Support in Acute Chest Syndrome Associated With Sickle Cell Disease: A Rare Report of a Common Case. ( 28703372 )
2017
36
Hemoglobin inhibits albumin uptake by proximal tubule cells: implications for sickle cell disease. ( 28356267 )
2017
37
Expression pattern of CD55 and CD59 on red blood cells in sickle cell disease. ( 27667587 )
2017
38
Daily Opioid Use Fluctuates as a Function of Pain, Catastrophizing, and Affect in Patients with Sickle Cell Disease: an Electronic Daily Diary Analysis. ( 28943232 )
2017
39
Assessing responsiveness over time of the PROMIS(Ar) pediatric symptom and function measures in cancer, nephrotic syndrome, and sickle cell disease. ( 28884421 )
2017
40
Bone marrow necrosis and fat embolism syndrome: a dreadful complication of hemoglobin sickle cell disease. ( 29259931 )
2017
41
The role of rs1984112_G at CD36 gene in increasing reticulocyte level among sickle cell disease patients. ( 27869039 )
2017
42
Innovative PCR without DNA extraction for African sickle cell disease diagnosis. ( 28929945 )
2017
43
Guidelines on red cell transfusion in sickle cell disease. Part I: principles and laboratory aspects. ( 28092109 )
2017
44
Prevalence and Clinical Characteristics of Rheumatoid Arthritis in an Inner City Population with Sickle Cell Disease. ( 28944097 )
2017
45
AAPT Diagnostic Criteria for Chronic Sickle Cell Disease Pain. ( 28065813 )
2017
46
Hemoglobin-Based Blood Substitutes and the Treatment of Sickle Cell Disease: More Harm than Help? ( 28054978 )
2017
47
Risk of Asymptomatic Bacteriuria among People with Sickle Cell Disease in Accra, Ghana. ( 28933357 )
2017
48
Laparoscopic cholecystectomy for cholelithiasis in children with sickle cell disease. ( 28555355 )
2017
49
Hydroxyurea treatment effect on children with sickle cell disease and obstructive sleep apnea. ( 28078488 )
2017
50
Regulation of Active ICAM-4 on Normal and Sickle Cell Disease RBCs via AKAPs Is Revealed by AFM. ( 28076805 )
2017

Variations for Sickle Cell Disease

ClinVar genetic disease variations for Sickle Cell Disease:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 HBB NM_000518.4(HBB): c.20A> T (p.Glu7Val) single nucleotide variant Pathogenic,protective rs334 GRCh37 Chromosome 11, 5248232: 5248232

Expression for Sickle Cell Disease

Search GEO for disease gene expression data for Sickle Cell Disease.

Pathways for Sickle Cell Disease

Pathways related to Sickle Cell Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 12.04 G6PD HBB HBG1 UGT1A1
2 11.65 HBB HBD HBG1 HBG2
3 10.68 HBA2 HBB VCAM1
4 10.61 HBA2 HBB SELP VCAM1

GO Terms for Sickle Cell Disease

Cellular components related to Sickle Cell Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 blood microparticle GO:0072562 9.46 HBA2 HBB HBD HBG2
2 endocytic vesicle lumen GO:0071682 9.26 HBA2 HBB
3 hemoglobin complex GO:0005833 9.02 HBA2 HBB HBD HBG1 HBG2
4 haptoglobin-hemoglobin complex GO:0031838 8.96 HBA2 HBB

Biological processes related to Sickle Cell Disease according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 response to hypoxia GO:0001666 9.7 EPO PGF VCAM1
2 response to ethanol GO:0045471 9.61 G6PD UGT1A1 VCAM1
3 leukocyte cell-cell adhesion GO:0007159 9.51 SELP VCAM1
4 calcium-mediated signaling using intracellular calcium source GO:0035584 9.48 SELP VCAM1
5 hydrogen peroxide catabolic process GO:0042744 9.46 HBA2 HBB
6 blood coagulation GO:0007596 9.46 HBB HBD HBG1 HBG2
7 response to nutrient GO:0007584 9.43 EPO UGT1A1 VCAM1
8 leukocyte tethering or rolling GO:0050901 9.4 SELP VCAM1
9 erythrocyte maturation GO:0043249 9.37 EPO G6PD
10 cell volume homeostasis GO:0006884 9.32 KCNN4 SLC12A4
11 response to lipopolysaccharide GO:0032496 9.26 EPO SELP UGT1A1 VCAM1
12 oxygen transport GO:0015671 9.02 HBA2 HBB HBD HBG1 HBG2
13 transport GO:0006810 10.04 HBA2 HBB HBD HBG1 HBG2 KCNN4

Molecular functions related to Sickle Cell Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 iron ion binding GO:0005506 9.65 HBA2 HBB HBD HBG1 HBG2
2 heme binding GO:0020037 9.55 HBA2 HBB HBD HBG1 HBG2
3 peroxidase activity GO:0004601 9.37 HBA2 HBB
4 oxygen binding GO:0019825 9.35 HBA2 HBB HBD HBG1 HBG2
5 haptoglobin binding GO:0031720 9.32 HBA2 HBB
6 oxygen carrier activity GO:0005344 9.02 HBA2 HBB HBD HBG1 HBG2

Sources for Sickle Cell Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....